NBI-98854CAS# 171598-74-6 |
- Limonin
Catalog No.:BCN6057
CAS No.:1180-71-8
- Fosamprenavir Calcium Salt
Catalog No.:BCC1581
CAS No.:226700-81-8
- HIV-1 integrase inhibitor
Catalog No.:BCC1618
CAS No.:544467-07-4
- BMS-626529
Catalog No.:BCC1427
CAS No.:701213-36-7
- HIV-1 integrase inhibitor 2
Catalog No.:BCC1619
CAS No.:957890-42-5
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 171598-74-6 | SDF | Download SDF |
| PubChem ID | 44249892 | Appearance | Powder |
| Formula | C19H29NO3 | M.Wt | 319.44 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Synonyms | (2R,3R,11bR)-rel-Dihydrotetrabenazine; (2R,3R,11bR)-rel-DHTBZ | ||
| Solubility | Soluble in DMSO | ||
| Chemical Name | (2S,3S,11bS)-9,10-dimethoxy-3-(2-methylpropyl)-2,3,4,6,7,11b-hexahydro-1H-benzo[a]quinolizin-2-ol | ||
| SMILES | CC(C)CC1CN2CCC3=CC(=C(C=C3C2CC1O)OC)OC | ||
| Standard InChIKey | WEQLWGNDNRARGE-XIRDDKMYSA-N | ||
| Standard InChI | InChI=1S/C19H29NO3/c1-12(2)7-14-11-20-6-5-13-8-18(22-3)19(23-4)9-15(13)16(20)10-17(14)21/h8-9,12,14,16-17,21H,5-7,10-11H2,1-4H3/t14-,16-,17-/m0/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | NBI-98854 is a potent, highly selective, VMAT2 inhibitor that is effective in regulating the levels of dopamine release during nerve communication.
IC50 value:
Target: VMAT2
NBI-98854 completed a Phase I single ascending dose clinical trial in healthy male volunteers in Canada under an approved Clinical Trial Application with Health Canada.This trial showed NBI-98854 to be generally safe and well tolerated. References: | |||||
NBI-98854 Dilution Calculator
NBI-98854 Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 3.1305 mL | 15.6524 mL | 31.3048 mL | 62.6096 mL | 78.262 mL |
| 5 mM | 0.6261 mL | 3.1305 mL | 6.261 mL | 12.5219 mL | 15.6524 mL |
| 10 mM | 0.313 mL | 1.5652 mL | 3.1305 mL | 6.261 mL | 7.8262 mL |
| 50 mM | 0.0626 mL | 0.313 mL | 0.6261 mL | 1.2522 mL | 1.5652 mL |
| 100 mM | 0.0313 mL | 0.1565 mL | 0.313 mL | 0.6261 mL | 0.7826 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
NBI-98854 is a potent, highly selective, VMAT2 inhibitor that is effective in regulating the levels of dopamine release during nerve communication.
- Nortadalafil
Catalog No.:BCC1806
CAS No.:171596-36-4
- Tadalafil
Catalog No.:BCC2281
CAS No.:171596-29-5
- Doederleinic Acid
Catalog No.:BCC8319
CAS No.:171596-14-8
- 10,11-Dihydro-24-hydroxyaflavinine
Catalog No.:BCN7440
CAS No.:171569-81-6
- Urocortin (rat)
Catalog No.:BCC5789
CAS No.:171543-83-2
- Alexidine dihydrochloride
Catalog No.:BCC2466
CAS No.:1715-30-6
- Myrislignan
Catalog No.:BCN1242
CAS No.:171485-39-5
- Salprionin
Catalog No.:BCN3162
CAS No.:171439-43-3
- Dammarenediol II 3-O-caffeate
Catalog No.:BCN6519
CAS No.:171438-55-4
- SLIGRL-NH2
Catalog No.:BCC3947
CAS No.:171436-38-7
- Otophylloside B 4'''-O-beta-D-cymaropyranoside
Catalog No.:BCN7522
CAS No.:171422-85-8
- Otophylloside B 4'''-O-alpha-L-cymaropyranoside
Catalog No.:BCN7511
CAS No.:171422-82-5
- Sildenafil Citrate
Catalog No.:BCC2276
CAS No.:171599-83-0
- Sodium Phenylbutyrate
Catalog No.:BCC2164
CAS No.:1716-12-7
- Nitidanin
Catalog No.:BCN1107
CAS No.:171674-89-8
- Compound 56
Catalog No.:BCC3615
CAS No.:171745-13-4
- S-Adenosyl-L-Methtonine
Catalog No.:BCN2231
CAS No.:17176-17-9
- 2-(1H-Indole-3-carboxamido)benzoic acid
Catalog No.:BCN1529
CAS No.:171817-95-1
- Euchrenone A10
Catalog No.:BCN3574
CAS No.:171828-81-2
- 17-Acetyloxy-6-chloro-1α-chloromethylpregna-4,6-diene-3,20-dione
Catalog No.:BCC8440
CAS No.:17183-98-1
- Cauloside A
Catalog No.:BCN6726
CAS No.:17184-21-3
- 3-O-Coumaroylarjunolic acid
Catalog No.:BCN7131
CAS No.:171864-20-3
- Tryprostatin A
Catalog No.:BCN6778
CAS No.:171864-80-5
- Palmatine chloride monohydrate
Catalog No.:BCC8228
CAS No.:171869-95-7
NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: A randomized, double-blind, placebo-controlled study.[Pubmed:26346941]
Mov Disord. 2015 Oct;30(12):1681-7.
BACKGROUND: Tardive dyskinesia is a persistent movement disorder induced by chronic neuroleptic exposure. NBI-98854 is a novel, highly selective, vesicular monoamine transporter 2 inhibitor. We present results of a randomized, 6-week, double-blind, placebo-controlled, dose-titration study evaluating the safety, tolerability, and efficacy of NBI-98854 for the treatment of tardive dyskinesia. METHODS: Male and female adult subjects with moderate or severe tardive dyskinesia were included. NBI-98854 or placebo was given once per day starting at 25 mg and then escalated by 25 mg to a maximum of 75 mg based on dyskinesia and tolerability assessment. The primary efficacy endpoint was the change in Abnormal Involuntary Movement Scale from baseline at week 6 scored by blinded, central video raters. The secondary endpoint was the Clinical Global Impression of Change-Tardive Dyskinesia score assessed by the blinded investigator. RESULTS: Two hundred five potential subjects were screened, and 102 were randomized; 76% of NBI-98854 subjects and 80% of placebo subjects reached the maximum allowed dose. Abnormal Involuntary Movement Scale scores for NBI-98854 compared with placebo were significantly reduced (p = 0.0005). Active drug was also superior on the Clinical Global Impression of Change-Tardive Dyskinesia (p < 0.0001). Treatment-emergent adverse event rates were 49% in the NBI-98854 and 33% in the placebo subjects. The most common adverse events (active vs. placebo) were fatigue and headache (9.8% vs. 4.1%) and constipation and urinary tract infection (3.9% vs. 6.1%). No clinically relevant changes in safety assessments were noted. CONCLUSION: NBI-98854 significantly improved tardive dyskinesia and was well tolerated in patients. These results support the phase 3 clinical trials of NBI-98854 now underway.
